37 research outputs found
Assessment of cyst content using mean gray value for discriminating endometrioma from other unilocular cysts in premenopausal women
Objective To assess whether the analysis of cyst content
using mean gray value (MGV) can discriminate ovarian
endometriomas from other unilocular ovarian cysts in
premenopausal women.
Methods Stored three-dimensional (3D) volumes from 54
unilocular ovarian cysts diagnosed in 50 premenopausal
women (mean age, 37 (range, 22–50) years) were
analyzed to calculate the MGV from cyst content. Cysts
with solid components or septations were excluded.
MGV was calculated in all cases with the Virtual
Organ Computer-aided AnaLysisTM technique. The Bmode
presumptive diagnosis based on the examiner’s
subjective impression was also recorded.
Results Sixteen of the cysts resolved spontaneously and
were given a final clinical diagnosis of hemorrhagic
functional cyst, while 38 cysts were removed surgically
(diagnosed histologically as seven simple cysts, three
hemorrhagic cysts, 20 endometriomas, five mucinous
cysts and three paraovarian cysts). B-mode diagnoses
were as follows: seven simple cysts, 18 hemorrhagic
cysts, 24 endometriomas, three mucinous cysts and two
paraovarian cysts. MGV was significantly higher in
ovarian endometrioma when compared with all other
kinds of cyst. The receiver–operating characteristics
curve showed that using an MGV cut-off ≥15.560
had a sensitivity of 85% and a specificity of 76.5%
for diagnosing ovarian endometrioma (area under the
curve, 0.831; 95% CI, 0.718–0.944). These figures were
similar to those for B-mode diagnosis (sensitivity, 90%;
specificity, 82%) (McNemar test, P = 1.000). Combining
B-mode and MGV gave a sensitivity of 80% and a
specificity of 91%.
Conclusion Cyst content MGV is higher in ovarian
endometrioma than it is in other unilocular ovarian cysts.
The diagnostic performance of MGV is similar to that of
the examiner’s subjective impression. The combination of
both criteria achieves the highest specificit
Ultrasonography and atypical sites of endometriosis
In the present pictorial we show the ultrasonographic appearances of endometriosis
in atypical sites. Scar endometriosis may present as a hypoechoic solid nodule with hyperechoic
spots while umbilical endometriosis may appear as solid or partially cystic areas with ill-defined
margins. In the case of endometriosis of the rectus muscle, ultrasonography usually demonstrates
a heterogeneous hypoechogenic formation with indistinct edges. Inguinal endometriosis is quite
variable in its ultrasonographic presentation showing a completely solid mass or a mixed solid
and cystic mass. The typical ultrasonographic finding associated with perineal endometriosis is
the presence of a solid lesion near to the episiotomy scar. Under ultrasonography, appendiceal
endometriosis is characterized by a solid lesion in the wall of the small bowel, usually well defined.
Superficial hepatic endometriosis is characterized by a small hypoechoic lesion interrupting the hepatic
capsula, usually hyperechoic. Ultrasound endometriosis of the pancreas is characterized by a small
hypoechoic lesion while endometriosis of the kidney is characterized by a hyperechoic small nodule.
Diaphragmatic endometriosis showed typically small hypoechoic lesions. Only peripheral nerves can
be investigated using ultrasound, with a typical solid appearance. In conclusion, ultrasonography
seems to have a fundamental role in the majority of endometriosis cases in “atypical” sites, in all the
cases where “typical” clinical findings are present
Imaging in gynecological disease (17): ultrasound features of malignant ovarian yolk sac tumors (endodermal sinus tumors)
Objective To describe the clinical and sonographic
characteristics of malignant ovarian yolk sac tumors
(YSTs).
Methods In this retrospective multicenter study, we
included 21 patients with a histological diagnosis of
ovarian YST and available transvaginal ultrasound
images and/or videoclips and/or a detailed ultrasound
report. Ten patients identified from the International Results All cases were pure YSTs, except for one that
was a mixed tumor (80% YST and 20% embryonal
carcinoma). Median age at diagnosis was 25 (interquartile
range (IQR), 19.5–30.5) years. Seventy-six percent
(16/21) of women had an International Federation of
Gynecology and Obstetrics (FIGO) Stage I–II tumor at
diagnosis. Fifty-eight percent (11/19) of women felt pain
during the ultrasound examination and one presented
with ovarian torsion. Median serum α-fetoprotein (S-AFP)
level was 4755 (IQR, 1071–25 303) μg/L and median
serum CA 125 level was 126 (IQR, 35–227) kU/L. On
ultrasound assessment, 95% (20/21) of tumors were
unilateral. The median maximum tumor diameter was
157 (IQR, 107–181) mm and the largest solid component
was 110 (IQR, 66–159) mm. Tumors were classified as either multilocular-solid (10/21; 48%) or solid (11/21;
52%). Papillary projections were found in 10% (2/21) of
cases. Most (20/21; 95%) tumors were well vascularized
(color score, 3–4) and none had acoustic shadowing.
Malignancy was suspected in all cases, except in the
patient with ovarian torsion, who presented a tumor with
a color score of 1, which was classified as probably benign.
Image and videoclip quality was considered as adequate
in 18/21 cases. On review of the images and videoclips, we
found that all tumors contained both solid components
and cystic spaces, and that 89% (16/18) had irregular, still
fine-textured and slightly hyperechoic solid tissue, giving
them a characteristic appearance.
Conclusion Malignant ovarian YSTs are often detected
at an early stage, in young women usually in the second
or third decade of life, presenting with pain and markedly
elevated S-AFP. On ultrasound, malignant ovarian YSTs
are mostly unilateral, large and multilocular-solid or solid,
with fine-textured slightly hyperechoic solid tissue and
rich vascularization. © 2020 The Authors. Ultrasound
in Obstetrics & Gynecology published by John Wiley
& Sons Ltd on behalf of the International Society of
Ultrasound in Obstetrics and Gynecology
Linee guida sulla isotretinoina - consensus
Qualche anno addietro, si sparse la notizia che l'isotretinoina orale sarebbe stata ritirata dal commercio. In quel periodo fu pubblicato sugli Annales de Dermatologie un articolo scritto da un dermatologo francese preoccupato per quanto sarebbe successo a noi dermatologi, privati della isotretinoina orale, nella gestione dei pazienti con acne grave. Si prospettava un quadro di desolante ritorno al passato con \uec pazienti vittime di decisioni amministrative, scientificamente morto discutibili, prese con superficialit\ue0. Fortunatamente questo non accadde vista la infondatezza delle argomentazioni accusatorie avanzate. Da questa vicenda emerse la consapevolezza che alla base di quanto successo c'era una preoccupante disinformazione sulle caratteristiche del farmaco estesa ad ampie fasce di soggetti coinvolti nella gestione e nell'utilizzo del prodotto, medici di medicina generale, pediatri, farmacisti e pazienti. Alla luce di questo abbiamo sentito l'esigenza di colmare questa lacuna e di preparare una nota informativa, chiara e completa, sulle caratteristiche dell'isotretinoina orale.
Tale documento era diretto, con modalit\ue0 e contenuti opportunamente adattati, alle singole categorie sopra riportate. L'obiettivo finale era quello di evitare che, a pazienti effettivamente bisognosi di tale trattamento, esso fosse negato con motivazioni inconsistenti o per disinformazione. Il lavoro congiunto di un board di dermatologi, appartenenti alle Societ\ue0 pi\uf9 rappresentative della Dermatologia Italiana, ha portato alla definizione di due documenti informativi sull'isotretinoina orale. Il primo \ue8 indirizzato a medici di medicina generale, pediatri e farmacisti ed il secondo ai pazienti. \uc8 in programmazione per il prossimo futuro la preparazione di linee guida aggiornate sull'utilizzo del farmaco ad uso dei dermatologi
The immune microenvironment in hormone receptor-positive breast cancer before and after preoperative chemotherapy
Purpose: Hormone receptor-positive/HER2-negative (HR+/HER2_) breast cancer is associated with low levels of stromal tumor-infiltrating lymphocytes (sTIL) and PD-L1, and demonstrates poor responses to checkpoint inhibitor therapy. Evaluating the effect of standard chemotherapy on the immune microenvironment may suggest new opportunities for immunotherapy-based approaches to treating HR+/HER2_ breast tumors. Experimental Design: HR+/HER2_ breast tumors were analyzed before and after neoadjuvant chemotherapy. sTIL were assessed histologically; CD8+ cells, CD68+ cells, and PD-L1 staining were assessed immunohistochemically; whole transcriptome sequencing and panel RNA expression analysis (NanoString) were performed. Results: Ninety-six patients were analyzed from two cohorts (n = 55, Dana-Farber cohort; n = 41, MD Anderson cohort). sTIL, CD8, and PD-L1 on tumor cells were higher in tumors with basal PAM50 intrinsic subtype. Higher levels of tissuebased lymphocyte (sTIL, CD8, PD-L1) and macrophage (CD68) markers, as well as gene expression markers of lymphocyte or macrophage phenotypes (NanoString or CIBERSORT), correlated with favorable response to neoadjuvant chemotherapy, but not with improved distant metastasis-free survival in these cohorts or a large gene expression dataset (N = 302). In paired pre-/postchemotherapy samples, sTIL and CD8+ cells were significantly decreased after treatment, whereas expression analyses (NanoString) demonstrated significant increase of multiple myeloid signatures. Single gene expression implicated increased expression of immunosuppressive (M2-like) macrophage-specific genes after chemotherapy. Conclusions: The immune microenvironment of HR+/ HER2_ tumors differs according to tumor biology. This cohort of paired pre-/postchemotherapy samples suggests a critical role for immunosuppressive macrophage expansion in residual disease. The role of macrophages in chemoresistance should be explored, and further evaluation of macrophagetargeting therapy is warranted
Vaginal wall thickness as potential biomarker of vaginal health. A proposal for standardized ultrasound measurement using three-dimensional transvaginal ultrasound
Vaginal wall thickness could be used as a biomarker of vaginal health. We propose a standardized method using three-dimensional (3D) ultrasound for measuring vaginal wall thickness. Fill the vagina with gel. Insert the endovaginal transducer into the vagina up to the middle third. In the sagittal plane, visualizing the cervix and vaginal fornices, capture a 3D volume of the upper third of the vagina. Using tomographic ultrasound imaging function in the sagittal plane and the posterior vaginal fornix as the reference obtain at least three axial planes of the vagina, separated by 1 cm. Measure the vaginal wall thickness at a distance of 2 cm from the posterior vaginal fornix at 12, 3, 6, and 9 o'clock. The reproducibility of measurements was high. Measurements of vaginal wall thickness can be reliably performed
Transvaginal ultrasound versus magnetic resonance imaging for diagnosing adenomyosis: A systematic review and head-to-head meta-analysis
Background: Transvaginal ultrasound (TVS) and magnetic resonance imaging (MRI) are used for the clinical diagnosis of adenomyosis.
Objectives: To compare the diagnostic accuracy of TVS and MRI for the diagnosis of adenomyosis.
Search strategy: A search of studies was performed in five databases comparing TVS and MRI for the diagnosis of adenomyosis from January 1990 to May 2022.
Selection criteria: Studies were eligible if they reported on the use of TVS and MRI in the same set of patients. The reference standard must be pathology (hysterectomy).
Data collection and analysis: The quality of studies was assessed using the QUADAS-2 tool. Pooled sensitivity and specificity of both techniques were estimated and compared.
Main results: Six studies comprising 595 women were included. The risk of bias of patient selection was high in three studies. The risk of bias for index tests and reference test was low. Pooled estimated sensitivity, specificity, positive likelihood ratio, and negative likelihood ratio for TVS were 75%, 81%, 3.9, and 0.31, respectively. These figures for MRI were 69%, 80%, 3.5, and 0.39, respectively. No statistically significant differences were found (p = 0.7509). Heterogeneity was high.
Conclusions: MRI and TVS have similar performances for the diagnosis of adenomyosis
Supplementary Material for: Transvaginal Sonography for the preoperative assessment of parametrial deep infiltrating endometriosis: a diagnostic accuracy study
Objective: To evaluate the diagnostic accuracy for parametria endometriosis (PE) of transvaginal sonography (TVS) performed following a systematic approach for the assessment of the lateral parametria.
Design: Diagnostic accuracy study based on a prospective observational design
Participants: All consecutive patients who underwent laparoscopic surgery for endometriosis between January 2016 and December 2020.
Setting: Endometriosis referral hospital
Methods: We prospectively collected clinical, imaging, and surgical data of all consecutive patients who underwent laparoscopic surgery for endometriosis between January 2016 and December 2020. A standardized technique with a systematic approach for the assessment of the lateral parametria following specific anatomic landmarks was used for the TVS. The diagnostic accuracy for PE of TVS was assessed using the intraoperative and pathologic diagnosis of PE as the gold standard.
Results: In 476 patients who underwent surgery, PE was identified in 114 out of 476 patients (23.95%): 91 left and 54 right PE out of 476 surgical procedures were identified (19.12% vs. 11.34%; p=0.001); bilateral involvement in 27.19% (31/114 patients) cases. The sensitivity of TVS for PE was 90.74% (79.70%-96.92%, 95% CI) for the right side and 87.91% (79.40%-93.81%, 95% CI) for the left side. The specificity was almost identical for both sides (98.58% vs. 98.18%). For the right parametrium, the positive likelihood ratio (PLR) and negative likelihood ratio (NLR) were 63.82 (28.70-141.90, 95% CI) and 0.09 (0.04-0.22, 95% CI), respectively. On the left parametrium, the PLR and NLR were 48.35 (23.12-101.4, 95% CI) and 0.12 (0.07-0.21, 95% CI), respectively. The diagnostic accuracy for right and left PE was 97.69% (95.90%-98.84%, 95%CI) and 96.22% (94.04%-97.74%, 95% CI), respectively.
Limitations: The principal limit is the high dependence of TVS on the operator experience. Therefore, although a standardized approach following precise definitions of anatomical landmarks was used, we cannot conclude that the observed accuracy of TVS for PE is the same for all sonographers. In this regard, the learning curve was not assessed. In the case of negative TVS for parametrial involvement with an absent intraoperative suspect, a complete dissection of the parametrium was not performed to avoid surgical complications; therefore, cases of minor PE may be missed, underestimating false negatives.
Conclusions: TVS performed following a systematic approach for assessing the lateral parametria seems to have good diagnostic accuracy for PE with large changes in posttest probability of parametrial involvement based on the TVS evaluation. Considering the clinical and surgical implications of PE, further studies implementing a standardized approach for assessing the parametrium by TVS are recommended to confirm our observations and implement a standardized protocol in clinical practice
Diagnostic accuracy of transvaginal sonography for detecting parametrial involvement in women with deep endometriosis: systematic review and meta-analysis
Objective
To evaluate the accuracy of transvaginal sonography (TVS) for detecting parametrial deep endometriosis, using laparoscopy as the reference standard.
Methods
A search was performed in PubMed/MEDLINE and Web of Science for studies evaluating TVS for detecting parametrial involvement in women with suspected deep endometriosis, as compared with laparoscopy, from January 2000 to December 2020. The Quality Assessment of Diagnostic Accuracy Studies-2 (QUADAS-2) tool was used to evaluate the quality of the studies. Pooled sensitivity, specificity and positive and negative likelihood ratios for TVS in the detection of parametrial deep endometriosis were calculated, and the post-test probability of parametrial deep endometriosis following a positive or negative test was determined.
Results
The search identified 134 citations. Four studies, comprising 560 patients, were included in the analysis. The mean prevalence of parametrial deep endometriosis at surgery was 18%. Overall, the pooled estimated sensitivity, specificity and positive and negative likelihood ratios of TVS in the detection of parametrial deep endometriosis were 31% (95% CI, 10–64%), 98% (95% CI, 95–99%), 18.5 (95% CI, 8.8–38.9) and 0.70 (95% CI, 0.46–1.06), respectively. The diagnostic odds ratio was 26 (95% CI, 10–68). Heterogeneity was high. Visualization of a lesion suspected to be parametrial deep endometriosis on TVS increased significantly the post-test probability of parametrial deep endometriosis.
Conclusion
TVS has high specificity but low sensitivity for the detection of parametrial deep endometriosis